Spero Therapeutics Inc (SPRO)

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)

Spero Therapeutics (NASDAQ:SPRO) shares climbed 16% on Thursday after the U.S. Food and Drug Administration approved Utebzi, a novel oral...

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including...

Form 8-K - Current report

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report